Headlines

MID WEB AD_Vertical left side 426 pixels (height) x 170 pixels (width).gif

MBS might be associated with improved survival in individuals aged 69 years and older with obesity

A matched analysis from Uk researchers has provided preliminary evidence that metabolic and bariatric surgery (MBS) might be associated with improved survival in individuals aged 69 years and older with obesity, and can be performed with acceptable short-term risk in a specialist setting. The aim of the study was to assess the effect of MBS on long-term survival in patients with obesity aged 69 years and older compared with those of a similar age with obesity who did not unde

MBS might be associated with improved survival in individuals aged 69 years and older with obesity

LVSG has a detrimental effect on lower oesophageal sphincter pressure and DeMeester Score post-surgery

Bariatric surgery boosts short-term employment, but long-term gains uncertain

Research

MBS might be associated with improved survival in individuals aged 69 years and older with obesity

Journal watch 29/10/2025

Welcome to our regular round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have looked far and wide to give you an overview of papers including bariatric surgery has become safer over time, higher hospital and surgeon MBS volumes were associated with lower short-term mortality, fewer complications and shorter hospital stays, pharmacologic management of post-bariatric hypoglycemia (PBH) shows promise but there is an urge

Cochrane reviews find GLP-1 drugs effective for weight loss, but more independent studies needed

Three new Cochrane reviews find evidence that GLP-1 drugs result in clinically meaningful weight loss, but industry-funded studies raise questions. The reviews were commissioned by the World Health Organization (WHO) to inform upcoming guidelines on the use of these drugs to treat obesity. The reviews, which examine the effects of three weight loss drugs known as GLP-1 receptor antagonists, have found that all three drugs result in clinically meaningful weight loss compared w

Pennington Biomedical awarded renewal of NIH-funded Center to advance metabolic disease research

Following a competitive review process, the National Institutes of Health (NIH) funding for Pennington Biomedical’s Metabolic Basis of Disease Center of Biomedical Research Excellence (COBRE) was renewed for an additional five years. This Phase II renewal builds on the momentum achieved since the center’s establishment in 2020, enabling continued support for young scientists who are focused on the mechanisms through which nutrition and metabolism contribute to health. Jackie

Higher hospital and surgeon volumes associated with better outcomes after BMS

Higher hospital and surgeon volumes were associated with lower short-term mortality, fewer complications and shorter hospital stays, after bariatric surgery, according to researchers from Technische Universität Berlin, Berlin, Germany. The association was more pronounced in higher-quality studies. Future research should aim to standardize volume definitions to improve comparability and support policy efforts to centralize care and enhance patient outcomes. The researchers per

BMI alone may not be enough to measure cardiometabolic disease

Body mass index (BMI) alone may not be enough to measure someone's risk of cardiometabolic disease, according to researchers at UTHealth Houston. The research, led by a team from the Border Health Research Cohort at UTHealth Houston School of Public Health, focused on the relationship between adiposity, or excess fat tissue, and cardiometabolic disease in adults. Cardiometabolic disease is a group of health problems like heart disease and diabetes that are often caused by thi

Obesity-related cancer rising among both younger and older adults worldwide

Researchers from The Institute of Cancer Research and Imperial College London have reported cancer incidence rates increased for several cancer, apart from colorectal cancer, increases occurred in both younger and older adults. The cancer types where incidence rates rose for both younger and older adults were all related to obesity. The researchers studied annual cancer incidence data from 2003 to 2017 from 42 countries in Asia, Europe, Africa, North and South America, and Au

Brain scans could predict future weight gain in people with mental disorders

A simple standard MRI brain scan could predict which people with mental illnesses will gain weight after their initial diagnosis, thereby increasing their risk of physical diseases, and which ones will not. Visualisation and performance of the BMI predictor. Credit: Nature Mental Health (2025). DOI: 10.1038/s44220-025-00522-3 "This would allow us to start targeted prevention against the weight gain frequently observed in this patient group," explained Professor Nikolaos Kouts

Sirona dual-polymer hydrogel aims to bridge gap in obesity treatments

Sirona - a dual-polymer hydrogel pill - could soon offer a new and affordable weight management treatment, following a successful clinical trial involving University of Bristol researchers. Sirona developed by Oxford Medical Products is a hydrogel-based pill that is designed to aid weight loss by reducing hunger. After it is swallowed, the pill expands in your stomach, making you feel full faster. This helps you eat less without needing strong medications or injections. In th

Ascletis completes enrolment in US study for once-monthly subcutaneous depot treatment GLP-1R agonist ASC30 for obesity

Ascletis Pharma has completed enrolment in the US Phase IIa study for its once-monthly subcutaneous (SQ) depot formulation (treatment formulation) of small molecule GLP-1 receptor (GLP-1R) agonist ASC30 for the treatment of obesity. All 65 participants are obese or overweight with at least one weight-related comorbidity. The Phase IIa study of ASC30 once-monthly SQ depot treatment formulation is a 12-week, randomised, double-blind, placebo-controlled and multi-centre study co

FDA approves Novo Nordisk’s oral semaglutide (Rybelsus) for CV risk reduction in T2DM adults

Novo Nordisk has received FDA approval for Rybelsus for reducing the risk of major adverse cardiovascular events (MACE) such as cardiovascular (CV) death, heart attack, or stroke in adults with type 2 diabetes who are at high risk for these events, whether they've had a prior CV event or not (primary and secondary prevention). Results of the SOUL trial reinforce the clinical profile of the semaglutide molecule, which has been studied across a variety of therapeutic areas. "Ev

Anti-obesity drug market expected to grow to $82.55 billion by 2032

The global anti-obesity drug market is estimated to increase in valve to $25.87 billion in 2025 and is expected to reach $82.55 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 18.01% from 2025 to 2032. This strong market growth is driven by the rising global prevalence of obesity and the increasing demand for effective pharmaceutical treatments, according to a re[ort by According to Coherent Market Insights (CMI). Additionally, advancements in drug formul

Industry

FDA approves Novo Nordisk’s oral semaglutide (Rybelsus) for CV risk reduction in T2DM adults

Medtimo files patent infringement complaint against Allurion

Pfizer to acquire Metsera and its next-generation obesity portfolio

EU approves Novo Nordisk’s oral semaglutide

All caught up?

See all news

New: Directory

Discover global suppliers of specialist bariatric services, treatments, products, and medical equipment.

Browse directory

Events

Headlines

MBS might be associated with improved survival in individuals aged 69 years and older with obesity

MBS might be associated with improved survival in individuals aged 69 years and older with obesity

MBS might be associated with improved survival in individuals aged 69 years and older with obesity

LVSG has a detrimental effect on lower oesophageal sphincter pressure and DeMeester Score post-surgery

Bariatric surgery boosts short-term employment, but long-term gains uncertain

Research

MBS might be associated with improved survival in individuals aged 69 years and older with obesity

Journal watch 29/10/2025

Cochrane reviews find GLP-1 drugs effective for weight loss, but more independent studies needed

Pennington Biomedical awarded renewal of NIH-funded Center to advance metabolic disease research

Higher hospital and surgeon volumes associated with better outcomes after BMS

BMI alone may not be enough to measure cardiometabolic disease

Obesity-related cancer rising among both younger and older adults worldwide

Brain scans could predict future weight gain in people with mental disorders

Sirona dual-polymer hydrogel aims to bridge gap in obesity treatments

Ascletis completes enrolment in US study for once-monthly subcutaneous depot treatment GLP-1R agonist ASC30 for obesity

FDA approves Novo Nordisk’s oral semaglutide (Rybelsus) for CV risk reduction in T2DM adults

Anti-obesity drug market expected to grow to $82.55 billion by 2032

Industry

FDA approves Novo Nordisk’s oral semaglutide (Rybelsus) for CV risk reduction in T2DM adults

Medtimo files patent infringement complaint against Allurion

Pfizer to acquire Metsera and its next-generation obesity portfolio

EU approves Novo Nordisk’s oral semaglutide

All caught up?

New: Directory

Discover global suppliers of specialist bariatric services, treatments, products, and medical equipment.

Events

(See all)

8TH Gulf Obesity Surgery Society International Conference

6th London International Bariatric Surgery Symposium (LIBSS)

Tweets

Back to Top